Trials / Unknown
UnknownNCT05942378
A Study of HRXG-K-1939 and Adebrelimab in Patients With Advanced Solid Tumors
A Phase 1 Study to Evaluate the Efficacy and Safety of HRXG-K-1939 and Adebrelimab in Patients With Advanced Solid Tumors
- Status
- Unknown
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- Sponsor
- Fudan University · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This is a Phase 1, open-label study evaluating the efficacy and safety of HRXG-K-1939 in combination with Adebrelimab (anti-programmed death-ligand 1 \[anti-PD-L1\] antibody) in patients with advanced solid tumors. HRXG-K-1939 will be administered to patients in a dose escalation regimen to determine a recommended dose for expansion.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | HRXG-K-1939 | HRXG-K-1939 |
| DRUG | Adebrelimab | Adebrelimab is a programmed death-ligand 1 antibody |
Timeline
- Start date
- 2023-07-01
- Primary completion
- 2025-09-01
- Completion
- 2025-12-01
- First posted
- 2023-07-12
- Last updated
- 2023-07-12
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05942378. Inclusion in this directory is not an endorsement.